A Phase I/II Study of TKM-080301, a RNAi Therapeutic Directed Against Polo-Like Kinase 1 (PLK1), in Patients with Gastrointestinal Neuroendocrine Tumors (GI-NET)
ClinicalTrials.gov Identifier: NCT01262235

Thorvardur R Halfdanarson; Tannaz Armaghany;
Samuel Ejadi; Donald W Northfelt; Ramesh K Ramanathan;
Jonathan Strosberg; David C Smith; Daniel Vaena;
Paul Fredlund; Sean C Semple; Sarabjit S Gahir;
Andrew Dye; Mark Kowalski

1Mayo Clinic, Rochester, MN, 55902
2Westchase Clinical Associates Houston, TX 77042
3Virginia G. Piper Cancer Center/TGen, Scottsdale, AZ 85258
4Mayo Clinic Scottsdale, AZ 85259
5Moffitt Cancer Center, Tampa FL 33612
6University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109
7Holden Comprehensive Cancer Center, Iowa City, IA 52242
8Tekmira Pharmaceuticals Corporation, Burnaby, BC, Canada V5J 5J8

Background: Polo-like kinase 1 (PLK1) regulates multiple critical aspects of cell progression, is highly expressed in many human tumors, and correlates negatively with patient outcome. TKM-080301 is a lipid nanoparticle formulation of a small interfering RNA (siRNA) directed against PLK1, a serine/threonine kinase that regulates multiple critical aspects of cell cycle progression and mitosis.

Methods: The previously reported dose escalation portion of this phase I/II open-label study supported a maximum tolerated dose (MTD) of 0.75 mg/kg/week. The study included an initial expansion cohort at the MTD in subjects with advanced solid tumors, and subsequent expansion cohorts in
subjects with adrenocortical carcinoma (ACC) and GI-NET. TKM-080301 was administered as a 30-minute IV infusion on Days 1, 8, and 15 of a 28-day cycle. Disease response according to RECIST 1.1 criteria was assessed following every two cycles of treatment.

**Results:** Fifteen previously treated subjects with GI-NET received TKM-080301; one subject was enrolled during the dose escalation phase and received two doses at 0.9 mg/kg and subsequently 0.6 mg/kg, one subject was enrolled during the initial expansion cohort at 0.75 mg/kg, the remaining 13 subjects were enrolled in the GI-NET expansion cohort at 0.75 mg/kg. In 13 GI-NET subjects who were evaluable, the best response observed was partial response (PR) for one subject (>60% reduction in tumor) and stable disease (SD) for 11 subjects (duration 1-52 weeks). Overall, 7/13 (54%) of subjects showed a best response of decrease in target tumor size (2.8% to 61%). The most common adverse events were: chills, nausea, vomiting, pyrexia, hypertension, fatigue, and increased AST. Serious adverse events considered at least possibly related to TKM-080301 were observed for three subjects in total included myocardial infarction (2 subjects), atrial fibrillation, and pulmonary edema.

**Conclusion:** This first-in-human trial indicates TKM-080301 was generally well-tolerated by the majority of subjects. In addition, promising evidence of anti-tumor effect has been observed in GI-NET.